Wednesday, 11 February 2015 08:00 AM
LAS VEGAS, NV / ACCESSWIRE / February 11, 2015 / EnzymeBioSystems (OTC:ENZB) announces that its preclinical methyl amooranin batch nears completion. Amooranin is the Company's lead pharmaceutical product. The Company plans to seek the use of methyl amooranin in the prevention of breast cancer.
"We expect the preclinical batch of methyl amooranin will be completed by the end of February, 2015," stated Gary Rojewski, CEO of EnzymeBioSystems. He went on to say, "This places us right on schedule to complete the required studies for submitting an Investigational New Drug Application to the FDA." He added, "The in vitro lab results and in vivo mice testing, appear to be promising for the reduction of tumors using methyl amooranin."
"As a precautionary note, there are no assurances that the company will ever obtain an IND for this compound," stated Mr. Rojewski.
About EnzymeBioSystems
EnzymeBioSystems produces specialty enzymes and enzyme related products. The Company plans to use enzyme technologies to develop commercial solutions for a broad range of applications within the pharmaceutical industry.
Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The company's actual results could differ materially from those anticipated in the forward-looking statements.
Contact:
Edward Zimmerman III
EnzymeBioSystems
Phone: (702) 631-4251
Email: [email protected]
7575
W. Washington Ave.
Las Vegas, NV 89128
SOURCE: EnzymeBioSystems